Iain Stephenson

Summary

Country: UK

Publications

  1. ncbi request reprint Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy
    Iain Stephenson
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 191:1210-5. 2005
  2. ncbi request reprint Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses
    Xiuhua Lu
    Influenza Branch, Centers for Disease Control and Prevention, USA
    Vaccine 24:6588-93. 2006
  3. ncbi request reprint Confronting the avian influenza threat: vaccine development for a potential pandemic
    Iain Stephenson
    Influenza Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet Infect Dis 4:499-509. 2004
  4. pmc Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
    Mary A Hoelscher
    Influenza Branch, Division of Rickettsial and Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 367:475-81. 2006
  5. ncbi request reprint Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study
    Iain Stephenson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW, UK
    Vaccine 25:4056-63. 2007
  6. pmc Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006
  7. doi request reprint Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1
    Iain Stephenson
    N Engl J Med 359:1631-3. 2008
  8. ncbi request reprint Development and evaluation of influenza pandemic vaccines
    Iain Stephenson
    Lancet Infect Dis 6:71-2. 2006
  9. ncbi request reprint Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 362:1959-66. 2003
  10. ncbi request reprint Clinical evaluation of vaccines for pandemic influenza H5N1
    Manish Pareek
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW
    Br J Hosp Med (Lond) 68:80-4. 2007

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy
    Iain Stephenson
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 191:1210-5. 2005
    ..0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5...
  2. ncbi request reprint Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses
    Xiuhua Lu
    Influenza Branch, Centers for Disease Control and Prevention, USA
    Vaccine 24:6588-93. 2006
    ..These results demonstrated that vaccination of mice with H5 IIV or LAIV induced a high degree of cross-protection from illness and death following lethal challenges with a heterologous H5N1 virus...
  3. ncbi request reprint Confronting the avian influenza threat: vaccine development for a potential pandemic
    Iain Stephenson
    Influenza Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet Infect Dis 4:499-509. 2004
    ..Adjuvanted or whole-virus preparations may improve immunogenicity and allow sparing of antigen...
  4. pmc Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
    Mary A Hoelscher
    Influenza Branch, Division of Rickettsial and Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 367:475-81. 2006
    ..However, currently licensed human vaccines are subtype-specific and do not protect against these H5N1 viruses. We aimed to develop an influenza vaccine and assessed its immunogenicity and efficacy to confer protection in BALB/c mice...
  5. ncbi request reprint Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study
    Iain Stephenson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW, UK
    Vaccine 25:4056-63. 2007
    ..This study raises concern about comparability of serology results from H5N1 vaccine trials and it is proposed that an International Standard for influenza H5N1 antibody is developed...
  6. pmc Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006
    ..The addition of the biovector to the vaccine given with 30 microg LTK63 enhanced mucosal IgA responses to A/Duck/Singapore (H5N3) (P=0.0491) and B/Guandong (P=0.0028) but not to A/Panama (H3N2). All vaccines were well tolerated...
  7. doi request reprint Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1
    Iain Stephenson
    N Engl J Med 359:1631-3. 2008
  8. ncbi request reprint Development and evaluation of influenza pandemic vaccines
    Iain Stephenson
    Lancet Infect Dis 6:71-2. 2006
  9. ncbi request reprint Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 362:1959-66. 2003
    ..In 1999, avian influenza A/Hong Kong/1073/99 (H9N2) virus emerged as a pandemic threat to human beings. We aimed to assess safety, tolerability, and antigenicity of whole virus and subunit H9N2 vaccines in healthy volunteers...
  10. ncbi request reprint Clinical evaluation of vaccines for pandemic influenza H5N1
    Manish Pareek
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW
    Br J Hosp Med (Lond) 68:80-4. 2007
    ..In 2004 the virus re-emerged among poultry and migratory birds in Asia and has spread into Europe and Africa, raising concerns that an H5 pandemic is imminent...
  11. ncbi request reprint Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center
    Anucha Apisarnthanarak
    Infectious Diseases Division, Thammasart University Hospital, Klong Luang, Pratumthani, Thailand 12120
    Clin Infect Dis 40:e16-8. 2005
    ..There was no serologic evidence of anti-H5 antibody reactivity or subclinical infection in either of the groups...
  12. ncbi request reprint H5N1 vaccines: how prepared are we for a pandemic?
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 368:965-6. 2006
  13. ncbi request reprint Development of vaccines against influenza H5
    Iain Stephenson
    Lancet Infect Dis 6:458-60. 2006
  14. ncbi request reprint Influenza: current threat from avian influenza
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Br Med Bull 75:63-80. 2005
    ..Oseltamivir has been stockpiled as part of influenza pandemic preparedness planning; however, the emergence of drug resistance may limit its clinical use...
  15. ncbi request reprint Are we ready for pandemic influenza H5N1?
    Iain Stephenson
    Leicester Royal Infirmary, Level 6, Windsor Building, Leicester, LE1 5WW, UK
    Expert Rev Vaccines 4:151-5. 2005
    ..Pandemic preparedness plans have been developed by national and international authorities but may be compromised by a lack of readily available interventions...
  16. ncbi request reprint Transmission of equine influenza virus to dogs
    P C Crawford
    College of Veterinary Medicine, University of Florida, Gainesville, FL 32611, USA
    Science 310:482-5. 2005
    ..Evidence of infection in pet dogs suggests that this infection may also become enzootic in this population...
  17. ncbi request reprint Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Vaccine 21:1687-93. 2003
    ..001). MF59 significantly increased GMTs of antibody when compared to non-adjuvanted vaccine (P<0.001)...